Goldman Sachs
ANRO icon

Goldman Sachs’s Alto Neuroscience ANRO Stock Holding History

Goldman Sachs’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.25M Buy
236,830
+132,113
+126% +$3.05M ﹤0.01% 3684
2026
Q1 		$2.35M Sell
104,717
-51,602
-33% -$956K ﹤0.01% 4393
2025
Q4 		$2.78M Buy
156,319
+66,068
+73% +$832K ﹤0.01% 4285
2025
Q3 		$363K Sell
90,251
-75,836
-46% -$251K ﹤0.01% 5667
2025
Q2 		$365K Buy
166,087
+65,713
+65% +$156K ﹤0.01% 5338
2025
Q1 		$217K Sell
100,374
-10,903
-10% -$39K ﹤0.01% 5605
2024
Q4 		$471K Buy
111,277
+65,740
+144% +$410K ﹤0.01% 5282
2024
Q3 		$521K Buy
45,537
+31,382
+222% +$384K ﹤0.01% 5027
2024
Q2 		$151K Buy
+14,155
New +$184K ﹤0.01% 5331

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Goldman Sachs's ANRO Position: Q2 2026 in Review

Goldman Sachs increased its Alto Neuroscience (ANRO) stake by 126% in Q2 2026, buying an estimated $3.05M and bringing the position to 236,830 shares worth $6.25M. The position accounts for ﹤0.01% of the portfolio, ranked #3684.

Goldman Sachs first reported a position in ANRO in Q2 2024 and has held it in 9 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Goldman Sachs held 236,830 shares of Alto Neuroscience worth $6.25M as of Q2 2026.
  • Goldman Sachs bought 132,113 Alto Neuroscience shares in Q2 2026, an estimated $3.05M.
  • Alto Neuroscience made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3684 holding.
  • Goldman Sachs first reported a position in Alto Neuroscience in Q2 2024 and has held it in 9 quarters since.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.